Risk of insulin resistance with statin therapy in individuals without dyslipidemia: A propensity-matched analysis in a registry population
- Authors
- Hyun, Myung Han; Jang, Jae Won; Choi, Byoung Geol; Na, Jin Oh; Choi, Cheol Ung; Kim, Jin Won; Kim, Eung Ju; Rha, Seung-Woon; Park, Chang Gyu; Lee, Eunmi; Seo, Hong Seog
- Issue Date
- 6월-2020
- Publisher
- WILEY
- Keywords
- dyslipidemia; insulin resistance; statin
- Citation
- CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, v.47, no.6, pp.947 - 954
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Volume
- 47
- Number
- 6
- Start Page
- 947
- End Page
- 954
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/55537
- DOI
- 10.1111/1440-1681.13272
- ISSN
- 0305-1870
- Abstract
- Several studies suggest the higher vulnerability of individuals with lower low-density lipoprotein cholesterol (LDL-C) levels to diabetes mellitus. However, the discordance between high and low baseline LDL-C levels shown by statin-induced insulin resistance is not fully understood. This study aimed to explore the relationship between baseline LDL-C levels and the risk of statin-induced insulin resistance during statin therapy. In total, 2660 (451 with dyslipidemia and 2209 without dyslipidemia) consecutive patients were enrolled. Their baseline clinical data were adjusted using a propensity score matching analysis, using the logistic regression model. Insulin resistance index was based on the homeostatic model assessment-insulin resistance (HOMA-IR) and was monitored for a median of 2 years. Among the individuals who received statin therapy, those with and without dyslipidemia showed significantly decreased LDL-C levels (all P < .0001) and significantly increased fasting plasma insulin levels (Delta = +24.1%, P = .0230; Delta = +30.1%, P < .0001); however, their glycated haemoglobin A1c and fasting blood glucose levels did not change (all P > .05). Although HOMA-IR was positively associated with statin therapy in individuals with and without dyslipidemia, statistically significant difference during follow-ups was observed only in individuals without dyslipidemia (Delta = +15.6%, P = .1609; Delta = 24.0%; P = .0001). Insulin resistance was higher in statin users without baseline dyslipidemia than in those with dyslipidemia. Thus, statin therapy could increase the risk of statin-induced insulin resistance in individuals with normal baseline cholesterol levels.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.